Search Results

By Michael J Kraut, MD  / March 15 2012

Cost of Cancer Therapy: The Elephant in the Room?

I am distressed by your coverage of innovative therapies, such as dual HER2 blockade (see The ASCO Post, January 1, 2012, and Supplement to February 15, 2012), without mentioning that these therapies will never be cost-effective given the current pricing of the agents involved. If we wish to...